Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2000 | Paper Report

Estrogen receptor β in breast cancer

Author: Balvinder Shoker

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Approximately 30-40% of hormone receptor positive breast cancers do not respond to endocrine therapy. The recent discovery of ERβ suggests that the mechanism of action of estrogens is more complex than at first thought. Estrogens bind ERβ with affinity similar to ERα and the transcriptional activation is identical for both receptor forms. Furthermore ERα and ERβ can form biologically functional receptor heterodimers. However, little is known about ERβ expression and its role in breast cancer. …
Literature
1.
Jarvinen TAH, Pelto-Huikkl M, Holli K, Isola J: Estrogen receptor β is coexpressed with ERa and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 2000, 156: 29-35.CrossRefPubMedPubMedCentral
Metadata
Title
Estrogen receptor β in breast cancer
Author
Balvinder Shoker
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2000-66708

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Paper Report

Dual HER-2/EGFR tyrosine kinase inhibitors

Paper Report

Endocrine response: Is CGAthe key?

Research article

BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite

Review

Breast imaging technology: Probing physiology and molecular function using optical imaging - applications to breast cancer

Paper Report

Comparison of different methods of HER-2 analysis in archival tissue

Paper Report

An anti-oncogenic role for decorin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits